CAPRICOR THERAPEUTICS Aktie

 

SAN FRANCISCO, Sept. 17, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......

BENSALEM, Pa., Sept. 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Capricor Therapeutics, Inc. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR......

A securities class action alleges Capricor Therapeutics did not follow the pre-specified blinding and protocol procedures for its Phase 3 HOPE-3 trial, with FDA later noting that the final study protocol deviated from the associated statistical analysis plan. NEW YORK, Sept. 17, 2026......

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until......

LOS ANGELES, Sept. 16, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Capricor Therapeutics, Inc. (CAPR) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR......

Capricor Therapeutics shares collapsed from $19.70 to $4.19 following FDA briefing documents and an adverse advisory committee vote, falling an aggregate 15.08 per share across two corrective-disclosures, or 78.7%, according to allegations in a pending securities class action. NEW YORK,......

SAN DIEGO, Sept. 15, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR). NASDAQ: CAPR investors should contact the Shareholders Foundation at......

SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......

Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Leading securities law firm......

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK, Sept. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead......

NEW YORK and NEW ORLEANS, Sept. 11, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NasdaqGS: CAPR) of a class action......

LOS ANGELES, Sept. 11, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

LOS ANGELES, Sept. 11, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a)......

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......

SAN DIEGO, Sept. 10, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, all dates inclusive (the "Class Period"), have until......

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Capricor to Contact Him Directly to Discuss Their Options NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds......

SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the......